Xeris Pharmaceuticals (0A8E) Income Statement
Xeris Pharmaceuticals Income Statement
Last quarter (Q2 2026), Xeris Pharmaceuticals's total revenue was $92.10M, an increase of 28.74% from the same quarter last year. In Q2, Xeris Pharmaceuticals's net income was $-31.10M. See Xeris Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 291.85M | $ 203.07M | $ 163.91M | $ 110.25M | $ 49.59M | |
| $ 238.43M | $ 166.24M | $ 135.27M | $ 87.61M | $ 36.27M | |
| $ 213.54M | $ 199.88M | $ 179.28M | $ 169.55M | $ 151.43M | |
| Depreciation and Amortization | $ 12.16M | $ 12.63M | $ 13.16M | $ 12.67M | $ 1.88M |
| $ 12.71M | $ -13.99M | $ -23.73M | $ -69.31M | $ -113.67M | |
| $ 24.90M | $ -33.65M | $ -44.01M | $ -81.94M | $ -115.16M | |
| $ -24.34M | $ -23.46M | $ -19.49M | $ -14.14M | $ -7.57M | |
| $ 554.00K | $ -57.10M | $ -63.50M | $ -96.08M | $ -122.72M | |
| $ 554.00K | $ -54.84M | $ -62.26M | $ -94.66M | $ -122.72M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.00 | $ -0.37 | $ -0.45 | $ -0.70 | $ -1.55 |
| Diluted EPS | $ 0.00 | $ -0.37 | $ -0.45 | $ -0.70 | $ -1.55 |
| Weighted Average Shares Outstanding | 160.43M | 146.77M | 137.67M | 135.63M | 79.03M |
| Weighted Average Shares Outstanding (Diluted) | 172.74M | 146.77M | 137.67M | 135.63M | 79.03M |
Currency in USD
